Atai Beckley (ATAI) Stock Analysis

What Atai Beckley does

Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.

Key metrics

ETFs linked to ATAI

Broad-market and Healthcare sector ETFs an investor holding Atai Beckley is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ATAI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Atai Beckley?

Atai Beckley trades under the ticker ATAI on NASDAQ.

Which exchange is ATAI listed on?

ATAI is listed on NASDAQ.

What sector does Atai Beckley operate in?

Atai Beckley is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ATAI in a portfolio?

PortView shows ATAI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.